ArticleFrontiers in bioinformatics2025
Functional and structural impacts of oncogenic missense variants on human polo-like kinase 1 protein.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoinformatic-guided design of a polo-like kinase 1 (PLK1)-targeted multi-epitope vaccine with preliminaryFrontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The polo-like kinase 1 (PLK1), a master key mitotic regulator, is frequently expressed in various types of cancers and associated with poor prognosis. The missense mutations in PLK1 may compromise its structural integrity and functional interactions, contributing to tumorigenesis. Methods: This study utilized a comprehensive computational pipeline to identify deleterious missense variants across multiple cancers. 207 non-synonymous single nucleotide polymorphisms (nsSNPs) were retrieved from cBioPortal, and 11 high-risk variants were prioritized using functional and structural prediction tools, such as SIFT, PolyPhen-2, I-mutant 2.0, and so on. Prognostic prevalence was evaluated via Kaplan-Meier survival analysis, and functional networks were explored using STRING. The structural dynamics of modeled mutations were analyzed through molecular dynamic simulations over 100 ns. Results: The kinase domain mutations such as L244F, R293C, and R293H and polo-box domain mutations such as A520T were found to cause deviations in structural stability, flexibility, solvent exposure, and compactness compared to wild-type. Further, PLK1 overexpression correlated with poor overall survival of patient outcomes in many types of cancers, including breast, liver, lung, kidney, and pancreatic cancers. Protein-protein interaction revealed PLK1's involvement in oncogenic pathways. Discussion: The study highlights the structural and functional implications of oncogenic PLK1 mutations, emphasizing their role in cancer progression. Integrating predictive and dynamic exploration approaches facilitates prioritization of variants with potential clinical relevance. Conclusion: The nsSNPs in PLK1 may perturb conformational stability and functions of the protein. Further experimental validation and discovery of novel inhibitors might develop mutation-specific interventions in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.